Open AccessUS Food and Drug Administration Disruption of Generic Drug Market Increases Hospital Costs
Author(s) -
Philip J Almeter,
Jonathan A. Labuhn,
Peter E. Morris,
Eugene A. Hessel
Publication year - 2018
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0000000000003589
Subject(s) - medicine , vial , neostigmine , food and drug administration , vasopressin , drug , emergency medicine , anesthesia , medical emergency , pharmacology , chemistry
The purpose of the US Food and Drug Administration's Marketed Unapproved Drugs Initiative is to decrease marketing of older unapproved medications. The administration has recently extended its rulings by including sterile injectable drugs administered in the inpatient environment. The impact of this initiative on the inpatient environment has been minimally studied.